CTLA4 and bladder transitional cell carcinoma: It has been suggested that the expression levels of classical ICGs such as CTLA4, PD-1, and PD-L1 may not accurately identify patients who may benefit from immunotherapy, and a comprehensive analysis of ICGs in bladder tumor tissues may be able to more accurately assess the responsiveness of BLCA patients to immunotherapy22.